Company / Revenue per Share
Matinas BioPharma Holdings, Inc. Revenue per Share History
FY2015-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue per Share
$0.01
FY2023
5-year range
$0.00 / $0.01
FY2019-FY2023
Trend
+9516.4%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Revenue per Share changed +9516% YoY in FY2023, a notable deviation from the 7-year average annual change of +1319%.
Based on SEC 10-K filings.
0.01 in FY2023 with a 5-year CAGR of +55.7%.
Improved from $0.00 to $0.01 over the past 2 years.
Revenue per Share over time
Growth rates
- 3-Year CAGR
- +147.3%
- 5-Year CAGR
- +55.7%
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2023, revenue per share increased 9516.4% year-over-year.
- Lowest revenue per share in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -18.50 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Revenue per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | - | - |
| FY2023 | $0.01 | +9516.4% |
| FY2022 | $0.00 | -7.5% |
| FY2021 | $0.00 | -83.0% |
| FY2020 | $0.00 | -8.2% |
| FY2019 | $0.00 | -34.1% |
| FY2018 | $0.00 | -52.1% |
| FY2017 | $0.00 | - |
| FY2016 | $0.00 | -100.0% |
| FY2015 | $0.01 | - |
As of FY2023 · SEC 10-K · Updated Jun 24, 2026